drugset
drugset / Trial / NCT04854928

Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

NCT04854928 ↗

Phase 2 Unknown 60 enrolled Pharma Holdings AS CTC Clinical Trial Consultants AB · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase IIa, double-blind, placebo-controlled, randomised study designed to evaluate the effect, safety and tolerability of LTX-109 administered topically to the anterior nares in subjects with COVID-19 infection.

Timeline

Start
2021-05-03
Primary completion
2022-02
Completion
2022-05

Drugs

EvaluationDrugModalityDoseRoute
Subject LTX-109 Peptide 3 % Intranasal

Indications

COVID-19